BR112023000932A2 - Tetra-hidropirazolo-pirazinil-di-hidroimidazolona ou compostos de tetra-hidropirazolo-piridinil-di-hidroimidazolona e métodos de uso dos mesmos - Google Patents
Tetra-hidropirazolo-pirazinil-di-hidroimidazolona ou compostos de tetra-hidropirazolo-piridinil-di-hidroimidazolona e métodos de uso dos mesmosInfo
- Publication number
- BR112023000932A2 BR112023000932A2 BR112023000932A BR112023000932A BR112023000932A2 BR 112023000932 A2 BR112023000932 A2 BR 112023000932A2 BR 112023000932 A BR112023000932 A BR 112023000932A BR 112023000932 A BR112023000932 A BR 112023000932A BR 112023000932 A2 BR112023000932 A2 BR 112023000932A2
- Authority
- BR
- Brazil
- Prior art keywords
- dihydroimidazolone
- tetrahydropyrazole
- pyridinyl
- pyrazinyl
- compounds
- Prior art date
Links
- -1 TETRAHYDROPYRAZOLE-PYRAZINYL-DIHYDROIMIDAZOLONE Chemical compound 0.000 title abstract 4
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
tetra-hidropirazolo-pirazinil-dihidroimidazolona ou compostos de tetrahidropirazolo-piridinil-di-hidroimidazolona e métodos de uso dos mesmos. a presente invenção refere-se a um composto de fórmula (i): (i), ou um sal, hidrato, solvato, profármaco, estereoisômero ou tautômero farmaceuticamente aceitável do mesmo, que modula a atividade do receptor de glp-1, uma composição farmacêutica compreendendo um composto de fórmula (i) e um método de tratamento ou prevenção de uma doença na qual o receptor de glp-1 desempenha um papel.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020102955 | 2020-07-20 | ||
CN2021070120 | 2021-01-04 | ||
PCT/CN2021/107216 WO2022017338A1 (en) | 2020-07-20 | 2021-07-20 | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023000932A2 true BR112023000932A2 (pt) | 2023-10-03 |
Family
ID=77167918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023000932A BR112023000932A2 (pt) | 2020-07-20 | 2021-07-20 | Tetra-hidropirazolo-pirazinil-di-hidroimidazolona ou compostos de tetra-hidropirazolo-piridinil-di-hidroimidazolona e métodos de uso dos mesmos |
Country Status (14)
Country | Link |
---|---|
US (2) | US20230051320A1 (pt) |
EP (1) | EP4182020A1 (pt) |
JP (1) | JP2023534983A (pt) |
KR (1) | KR20230048056A (pt) |
CN (1) | CN116390926A (pt) |
AU (1) | AU2021311567A1 (pt) |
BR (1) | BR112023000932A2 (pt) |
CA (1) | CA3186217A1 (pt) |
CL (1) | CL2023000196A1 (pt) |
CO (1) | CO2023001407A2 (pt) |
IL (1) | IL299704A (pt) |
MX (1) | MX2023000943A (pt) |
PE (1) | PE20230854A1 (pt) |
WO (1) | WO2022017338A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023016546A1 (en) * | 2021-08-12 | 2023-02-16 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
CN117447493A (zh) * | 2023-12-25 | 2024-01-26 | 药康众拓(北京)医药科技有限公司 | 氘代吲哚嗪类化合物、药物组合物及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
EP3759110A1 (en) * | 2018-02-28 | 2021-01-06 | Novartis AG | Indole-2-carbonyl compounds and their use for the treatment of hepatitis b |
-
2021
- 2021-07-20 BR BR112023000932A patent/BR112023000932A2/pt unknown
- 2021-07-20 WO PCT/CN2021/107216 patent/WO2022017338A1/en active Application Filing
- 2021-07-20 MX MX2023000943A patent/MX2023000943A/es unknown
- 2021-07-20 JP JP2023504008A patent/JP2023534983A/ja active Pending
- 2021-07-20 PE PE2023000103A patent/PE20230854A1/es unknown
- 2021-07-20 KR KR1020237005845A patent/KR20230048056A/ko unknown
- 2021-07-20 CA CA3186217A patent/CA3186217A1/en active Pending
- 2021-07-20 EP EP21749074.7A patent/EP4182020A1/en active Pending
- 2021-07-20 US US17/380,084 patent/US20230051320A1/en active Pending
- 2021-07-20 IL IL299704A patent/IL299704A/en unknown
- 2021-07-20 AU AU2021311567A patent/AU2021311567A1/en active Pending
- 2021-07-20 CN CN202180063652.8A patent/CN116390926A/zh active Pending
- 2021-11-02 US US17/516,932 patent/US11584751B1/en active Active
-
2023
- 2023-01-19 CL CL2023000196A patent/CL2023000196A1/es unknown
- 2023-02-09 CO CONC2023/0001407A patent/CO2023001407A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3186217A1 (en) | 2022-01-27 |
US11584751B1 (en) | 2023-02-21 |
US20230051320A1 (en) | 2023-02-16 |
CN116390926A (zh) | 2023-07-04 |
KR20230048056A (ko) | 2023-04-10 |
EP4182020A1 (en) | 2023-05-24 |
CO2023001407A2 (es) | 2023-02-16 |
MX2023000943A (es) | 2023-02-22 |
IL299704A (en) | 2023-03-01 |
JP2023534983A (ja) | 2023-08-15 |
PE20230854A1 (es) | 2023-05-29 |
WO2022017338A1 (en) | 2022-01-27 |
AU2021311567A1 (en) | 2023-02-16 |
CL2023000196A1 (es) | 2023-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202307575B (en) | Methods and modified nucleosides for treating coronavirus infections | |
PH12021550995A1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
BR112023000932A2 (pt) | Tetra-hidropirazolo-pirazinil-di-hidroimidazolona ou compostos de tetra-hidropirazolo-piridinil-di-hidroimidazolona e métodos de uso dos mesmos | |
MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
BR112021021718A2 (pt) | Moduladores de thr-ss e métodos de uso dos mesmos | |
BR0314126A (pt) | Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio | |
NO20073357L (no) | 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien | |
AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
MX2021011647A (es) | Moduladores del receptor x4 de proteina g relacionado con mas y productos y metodos relacionados. | |
BRPI0614168A2 (pt) | Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto | |
BRPI0518222A (pt) | composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos | |
BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
BRPI0515991A (pt) | derivados de bisariluréia substituìda heterocìclica como inibidores de cinase | |
MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
PH12019500036A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
BR112022020814A2 (pt) | Métodos para tratamento de síndrome de liberação de citocina | |
MX2022008626A (es) | Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea. | |
BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
BR112021020297A2 (pt) | Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune | |
BR112022008786A2 (pt) | Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose | |
BR112021019817A2 (pt) | Compostos de pirrol | |
BR112021020027A2 (pt) | Compostos, composições e métodos | |
BR112022002107A2 (pt) | Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo | |
MX2023003476A (es) | Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados. |